Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
The First Percutaneously Implantable Multicolumn Directional Lead for Closed-Loop Spinal Cord Stimulation (cl-HERON)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Italy
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2415000.0
EU funding (EUR): 2415000.0
Participants: 1
Project status: SIGNED

WISE is a Milan-based medical device WISE specializing in advanced implantable leads for neuromonitoring and neuromodulation. Our leads leverage proprietary Supersonic Technology to create highly ergonomic, conformable, soft, and thin electrodes. These electrodes offer superior adhesion, minimal invasiveness, and excellent adaptability, overcoming the limitations of traditional technologies made from hard metal wires. Our flagship product, the CE-marked WISE Cortical Strip (WCS®), continuously records the brain’s spontaneous electrical activity. WISE is now introducing the cl-HERON® lead, a groundbreaking multicolumn paddle lead for spinal cord stimulation to treat chronic pain. Unlike conventional paddle leads that require complex neurosurgery, the cl-HERON® lead can be implanted percutaneously. It is compatible with closed-loop stimulation devices, enabling real-time recording and adjustment of stimulation in response to physiological changes such as breathing, heartbeat, and daily activities. The cl-HERON® lead reduces energy consumption by up to 60% compared to current cylindrical leads, thanks to directional stimulation, a high signal-to-noise ratio, and efficient data analysis. This innovation minimizes surgical complications and overall treatment costs (€169,769 vs. €186,139), resulting in significant healthcare savings. Founded in 2011 by CEO Luca Ravagnan and a team of material scientists, WISE has raised over €35 million. Our team of 37 members is highly experienced and gender-diverse, with 60% women and 10% holding PhDs. Our 1,600 m² manufacturing facility includes several R&D labs and a clean room dedicated to producing a wide range of devices. By 2032, the cl-HERON® lead is projected to provide innovative pain treatment to 24,000 patients annually, generating €96 million in revenue and capturing 15% of the global leads market.

Keywords: neuromonitoring,neuromodulation,spinal cord stimulation,closed loop stimulation,implantable leads,chronic pain treatment,directional stimulation
Emotional skills: The role of emotional intelligence for strategic interactions and markets (EMOSKILLS)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Individuals, Markets and Organisations
Panel description: Economics, finance , management
Countries involved: Netherlands
Call: ERC STARTING GRANTS (ERC-2022-STG, 2022)
Start date: 2023-01-01
End date: 2027-12-31
Duration (months): 60.0
Total project cost (EUR): 1396644.0
EU funding (EUR): 1396643.75
Participants: 1
Project status: SIGNED

Emotional intelligence, like anticipating the emotions of others and regulating one’s own emotions, is thought to be a crucial skill to do well in the workplace. This may be especially true for strategic interactions relevant for the workplace such as cooperation, bargaining, and market interactions. From experimental studies, we know that emotions play an important role in these interactions. Yet, whether or how emotional skills influence strategic interactions is unknown. Economists and other scholars currently lack the tools and framework to systematically study the role of emotional skills in strategic settings. While we have a good understanding of other key elements of strategic interactions like social preferences and strategic reasoning, no such investigation exists for emotional skills. The goal of this project is to provide the foundation to jumpstart the study of emotional skills in strategic interactions and markets. Specifically, this project addresses three main objectives. First, I will develop a new emotional skills test, specifically designed to study the role of emotional skills in strategic interactions. Second, the newly developed test allows me to experimentally investigate how emotional skills shape outcomes and decisions in strategic interactions and markets. Third, I will study the supply of emotional labor – the requirement that workers have to display certain emotions on the job that may mismatch their own – which is associated with considerable psychological costs. Despite its importance for labor markets, evidence on the economics of emotional labor is lacking. I will include emotional labor in standard economic models and develop a new experimental paradigm to estimate the supply of emotional labor. This project will synthesize insights from psychology and management with methods of experimental economics and will provide the experimental tools and paradigms to study emotional intelligence in strategic interactions and markets.

Keywords: emotions,strategic interaction,non cognitive skills,experimental economics,facial expressions
CO2 Utilisation Process via Looping tEchnology Demonstration (COUPLED)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Energy
Destination: Sustainable, secure and competitive energy supply
Action type: Innovation actions
Countries involved: United Kingdom,Spain,Italy,Belgium,Greece,Türkiye,Netherlands
Call: CCU for the production of fuels (HORIZON-CL5-2024-D3-02, 2024)
Start date: 2025-11-01
End date: 2029-10-31
Duration (months): 48.0
Total project cost (EUR): 9965927.46
EU funding (EUR): 7491637.71
Participants: 18
Project status: SIGNED

COUPLED is a holistic interdisciplinary project designed to demonstrate renewable fuel production seamlessly integrating three advanced technologies. The project encompasses optimal integration the demonstration in industrial settings (TRL7), detailed considerations of safety, environmental, societal, policy and business aspects for widespread adoption in the European energy sector. At its core, COUPLED combines: a) Chemical Looping Syngas generation thermally sustained, operated at high pressure, b) In-situ CO2 recovery using new class of membranes and c) Fischer Tropsch synthesis process, leveraging a structured reactor with a novel Fe-based catalyst optimized for CO2-rich feedstock. In combination, the proposed technologies will target an overall CO2-to-fuel conversion up 92% and the reduction of the production costs by 20% with respect to existing solutions for different industrial scenarios. Hence, the deployment of the technology at scale will support refineries, biogas and waste-to-energy processes in producing sustainable aviation fuels and renewable methanol production, and supply high-value fuel for steel manufacturing, contributing to the decarbonization of heavy industry. COUPLED includes research and technology organizations, relevant end users, catalyst suppliers technology specialists, fuel technology licensors and consultancy company ensuring expertise across the entire value chain. To maximize the industrial impact, the project will assess techno-economic, environmental a social acceptance, will develop an exploitation plan aiming to generate a sound business close to 60 b€ in revenues by 2050 given the market potential. The technology has the potential to use 6 mtpa of CO2 conversion into fuels from project partners by 2050, approximately 3% of the EU target in industrial CCU and carbon management by 2050.

Keywords: chemical looping,syngas,liquid fuels,ccu
A Pathway Towards Sustainable Use and Conservation of Cephalopod Stocks (SUCCEPHS)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Spain,Mexico
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2024-04-01
End date: 2027-03-31
Duration (months): 36.0
Total project cost (EUR): 210174.24
EU funding (EUR): 210174.24
Participants: 2
Project status: SIGNED

Our oceans provide food security, nutrition, poverty alleviation, and livelihoods for millions of people worldwide. However, environmental and social pressures (e.g., overfishing, climate change, population growth, globalization) threaten the oceans, the marine resources and the people depending on them. This is especially true for small-scale fisheries (SSF), which play a crucial (often neglected) role for local coastal communities. In this sense, alternative and effective ocean governance approaches are crucial for sustainable development and must adequately reflect the multi-dimensional and interconnected role of oceans in environmental health, economic prosperity, and human well-being. SUCCEPHS – ‘A Pathway Towards Sustainable Use and Conservation of Cephalopod Stocks’ aims to: i. demonstrate how existing tools to assess fisheries sustainability succeed or fail to integrate multiple dimensions of sustainability and achieve improved ocean governance; ii. identify common and context-specific factors that enable or hinder the achievement of sustainability in three octopus SSF; iii. improve the way octopus SSF sustainability is assessed and monitored. Embracing qualitative and quantitative data, and applying a participatory approach, SUCCEPHS will tackle simultaneously environmental, social and economic aspects of sustainability, while considering the particularities of fishing communities and resources, aiming to achieve improved governance to ensure equitable, sustainable and resilient octopus fisheries now and for generations to come. The project is designed to be a highly collaborative process, requiring stakeholders, partners and institutions to work together to co-create novel and adaptive tools for achieving these goals. A multi-comparative approach will allow a deep learning and information exchange throughout the process.

Keywords: sustainable fisheries small scale fisheries octopus fishing communities management
Scale Business and Technology to Impact on Disease Research by with Lossless and Efficient Data Analysis (BInno2scalek01)

Framework: Horizon Europe — Innovative Europe
Programme: European innovation ecosystems
Theme: Elevating the scalability potential of European business
Destination: Elevating the scalability potential of European business
Action type: Coordination and support actions
Countries involved: Germany
Call: Women TechEU (HORIZON-EIE-2021-SCALEUP-01, 2021)
Start date: 2022-07-01
End date: 2023-06-30
Duration (months): 12.0
Total project cost (EUR): 107142.86
EU funding (EUR): 75000.0
Participants: 1
Project status: CLOSED

Aren’t we expecting from disease research that all available data is being used? Yes! Yet one of the biggest hurdles is the data variety when to studying underlying mechanisms or prioritizing targets for novel treatments. Ultimately stalling projects and resulting in low output and quality. knowing01 GmbH is a deep tech software company founded in 2020 in Munich, Germany that gives Life Scientists full control of all their research data. Dr. Nikola Müller (founder and CEO) has spearheaded the project since 2014, when the idea budded during her academic research at Helmholtz Munich. The knowing01 solution is a software-as-a-service (SaaS) suite that allows the user to connect and explore omics data no matter their biodata type. Our innovative knowledge-graph based translation approach empowers scientists to run analyses across data types and compare different sets in their biological context. We additionally offer on client premise, licensed software. Our next challenging milestone is to scale a) by innovating the business and b) by having a critical assessment of the technology. We aim to exploit our niche market position. We are specifically aiming to be attractive to key partners that offer our together with their own services. We need scale our infrastructure and database-related technologies alongside with the business. Only both will allow us to future-proof our business paving the way for a sustainable business. Dr. Nikola Müller will profit from being part of the Women Leadership Program by sharpening negotiation skills, learning how to improve public visibility and finally, getting into potent female-friendly investor networks. Compared to classical IT, biotech or digital health companies, our offering opens a yet unexplored niche, which is why we will enormously profit from the Women TechEU grant. The non-dilutive funding will be critical of us being able to support the scale-developments to be able to move our business forward.

Keywords: life science,big data,knowledge graph,bioinformatics,growth,from data to insight
From cells to systems: Pioneering multi-level thrombosis risk prediction models - “ThromboRisk” (ThromboRisk)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Doctoral Networks
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Netherlands,Belgium,Germany,United Kingdom,Romania,Poland,Switzerland
Call: MSCA Doctoral Networks 2024 (HORIZON-MSCA-2024-DN-01, 2024)
Start date: 2026-02-01
End date: 2030-01-31
Duration (months): 48.0
Total project cost (EUR): 4436514.36
EU funding (EUR): 4436514.36
Participants: 18
Project status: SIGNED

Thrombosis, an occlusive blood clot, underlies ischemic stroke, myocardial infarction, and venous thrombosis, causing 1 in 4 deaths globally. Its incidence is rising due to an increasingly aging population and increased cardiovascular diseases, along with more cardiovascular implants. Unfortunately, limited understanding of thrombus formation, growth, and rupture hampers patient-specific prognosis. Current treatment strategies include antithrombotic therapy and thrombectomy, but improvements are needed for patient-specific treatments due to common recurrence and unknown impacts on clot fragmentation and thromboembolism. To effectively understand disease mechanisms and accurately predict treatment outcomes, it is crucial to integrate knowledge across multiple scales, harnessing a diverse range of cutting-edge in silico, in vitro, and in vivo technologies. This powerful fusion of emerging technologies holds the potential to revolutionize targeted and personalized medicine. However, there remains a significant shortage of trained professionals capable of co-creating such comprehensive and holistic disease models. ThromboRisk will therefore train 18 exceptional doctoral candidates (DCs) in diverse scientific fields, including mechanobiology, biochemistry, pathophysiology, and modeling. These researchers will collaborate within an international and interdisciplinary consortium to develop a platform advancing our understanding of thrombosis across scales, hereby bridging the gap between micro-level thrombus processes and macro-level impacts on disease prognosis, enabling clinical application. Unlike traditional engineering curricula, which address well-defined problems, ThromboRisk tackles complex, multifactorial "wicked problems" in fields of thrombosis by implementing a Challenge-Based Learning (CBL) doctoral training program to foster creativity, innovation, and societal impact. CBL is growing in undergraduate education but remains underdeveloped in doctoral training, where it has the potential to encourage DCs to step outside their comfort zones, think creatively, manage risks, and use technology responsibly in problem-solving. The DCs will work on real-world problems with peers, supervisors, consortium members, and external stakeholders, who act as "real clients" and co-creators.

Keywords: model based clinical decision support,thrombosis,computational modelling,multi scale modelling
CAR T cells Rewired to prevent EXhaustion in the tumour microenvironment (CAR T-REX)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Pathfinder
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Portugal,Spain,Germany,Hungary,Israel
Call: EIC Pathfinder Open 2022 (HORIZON-EIC-2022-PATHFINDEROPEN-01, 2022)
Start date: 2023-04-01
End date: 2027-06-30
Duration (months): 51.0
Total project cost (EUR): 2733931.25
EU funding (EUR): 2733931.25
Participants: 6
Project status: SIGNED

Although immunotherapy of select hematological malignancies using Chimeric Antigen Receptor (CAR) redirected T lymphocytes has recently gained regulatory approval, successful treatment of solid tumors using CAR T cells remains elusive. One salient problem is the limited efficacy and untimely exhaustion of CAR T cells in the tumor microenvironment (TME). Combining innovative methods of genome editing, chemistry and immunology, CAR T-REX proposes to explore a novel concept of building auto-regulated genetic circuits into CAR T cells to selectively circumvent their exhaustion upon activation in the TME. Genetic rewiring will be achieved by precisely inserting artificial miRNAs under endogenous exhaustion-related “Driver” promoters to downregulate “Target” genes that cause exhaustion. Proprietary technology enables specific replacement of the “Driver” gene without risking off-target mutations. Further advantages of combined insertion and silencing are (i) the ability to regulate when a gene is turned on/off by biologically and clinically relevant cellular cues, and (ii) multiple gene-knockdown with a single dsDNA cleavage and RNA-silencing of both alleles. These genetic modifications will be implemented using a novel high-performance peptide-based gene delivery platform with unlimited loading capacity, allowing combination of several types of cargo, as well as economical large scale GMP production. Rewired HER2/Neu (ErbB2) redirected CAR T cells will be tested on preclinical breast and gastric carcinomas, and variants that eliminate tumors resistant to conventional 2nd and 3rd generation peers (without adverse events) will be developed/manufactured following quality-by-design principles under GMP-like conditions, thus accelerating the pathway towards clinical translation. These approaches will also constitute a proof-of-concept for modifying therapeutic cell products, with the potential to considerably improve their safety, specificity, efficacy, scalability and cost.

Keywords: cancer immunotherapy,chimeric antigen receptor car t cells,solid tumours,t cell exhaustion
Building Excellence in Systems Immunology and Healthy Aging Research (SysAge)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Destination: Improved access to Excellence
Action type: Coordination and support actions
Panel: Life Sciences
Countries involved: Estonia,France,Denmark
Call: Twinning Bottom-Up (HORIZON-WIDERA-2023-ACCESS-02, 2023)
Start date: 2024-09-01
End date: 2027-08-31
Duration (months): 36.0
Total project cost (EUR): 1497287.81
EU funding (EUR): 1497287.81
Participants: 3
Project status: SIGNED

The demographic landscape of Europe is changing rapidly with an increasing number of old individuals. The increase in elderly people poses significant challenges for Europe in multiple spheres, notably in healthcare and its associated costs, as well as in overall wellbeing and cohesion of the European population. Healthy aging is therefore a crucial research and policy theme, and a healthy immune system is essential for this. Building upon the expertise in the molecular and cellular aspects of immune system function, excellent infrastructure and access to unique datasets of the Estonian Biobank, the University of Tartu (UTARTU) aims to become a world leader in research on age-related decline in immune function to address the societal challenge of age-related diseases and immunosenescence. To achieve this, UTARTU will partner with two excellent institutions in the fields of systems immunology and aging – Institut Pasteur (France) and the University of Copenhagen (Denmark). We will implement a wide range of activities to transfer to UTARTU knowledge and skills in 1. methodologies for studying molecular mechanisms in aging; 2. cutting-edge techniques for immunomonitoring; 3. big data and machine learning techniques for immunoprofiling; and 4. conducting healthy cohort and longitudinal studies. UTARTU will also receive guidance on interdisciplinarity aspects of healthy aging research, as well as on research management and commercialization. Partners will implement a pilot research project and prepare a joint research strategy to ensure long-term and mutually beneficial collaboration.

Keywords: healthy aging,systems immunology,immunomonitoring,immunoprofiling,big data
Translation Control in Development: when, where and how (TRANS-CODE)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Cell Biology, Development, Stem Cells and R egeneration
Panel description: For all organisms : Structure and function of the cell, cell -cell communication, embryogenesis, tissue differentiation, organogenesis, growth, development, evolution of development, organoids, stem cells, regeneration, therapeutic approaches
Countries involved: Netherlands
Call: ERC STARTING GRANTS (ERC-2025-STG, 2025)
Start date: 2025-11-01
End date: 2030-10-31
Duration (months): 60.0
Total project cost (EUR): 1500000.0
EU funding (EUR): 1500000.0
Participants: 1
Project status: SIGNED

The translation of mRNAs by ribosomes is a key step in decoding the information stored in our genome. Animal development requires a strict regulation of translation, in particular when transcription is absent, as in most early embryos. A range of mechanisms ensure that mRNAs are translated with the right efficiency and location, in the right cell types and exactly when their protein products are needed. Disruption of this regulation can lead to developmental defects and embryonic lethality. Despite the recognized importance of translation regulation, the impact of translation regulation, and especially localized translation, on protein levels remains largely unknown for most genes. Furthermore, the mechanisms that drive localized and cell-type-specific translation are poorly understood, partly due to a lack of methods that enable the real-time visualization of translation in live embryos. The goal of this proposal is to discover translationally regulated mRNAs across the genome in early development, and reveal, with single-molecule precision, how spatiotemporal cues and cell type-specific mechanisms drive differential protein translation. Using ribosome profiling, we will create a genome-wide single-cell map of translation efficiencies during embryonic development of C. elegans, thus delineating the translation landscape that guides development. Using real-time single-molecule translation imaging, we will reveal how local translation patterns are formed and maintained between and within cells. Finally, we will explore how RNA-binding proteins modulate both translation efficiencies and spatial organization, to reveal the underlying mechanisms that drive translation during development. This combination of genome-wide and single-molecule studies will lay the groundwork for understanding how spatial cues and cell-type-specific mechanisms drive precise protein expression, which ultimately shapes cellular identity in early development.

Keywords: translation regulation,development,c elegans,single molecule imaging,ribosome profiling,rna binding proteins